Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROHAN GARJE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1184902884
CMS profile
9005
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$10,277.21

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $9,150.00 2
Food and Beverage $712.55 12
Travel and Lodging $414.66 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $9,925.90 10
PFIZER INC. $172.79 2
Exelixis Inc. $133.64 1
Blue Earth Diagnostics $23.93 1
Merck Sharp & Dohme LLC $20.95 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROHAN GARJE

NPI 1184902884 · CMS profile ID 9005

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROHAN GARJE, NPI 1184902884, CMS profile ID 9005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ROHAN GARJE, NPI 1184902884, CMS profile ID 9005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ROHAN GARJE, NPI 1184902884, CMS profile ID 9005, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $10,277.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $6,700.0010/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200265232 CMS
Novartis Pharmaceuticals Corporation $69.3710/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200265234 CMS
Novartis Pharmaceuticals Corporation $414.6610/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200207656 CMS
Novartis Pharmaceuticals Corporation $24.0408/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200207646 CMS
Merck Sharp & Dohme LLC $20.9506/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238229306 CMS
Blue Earth Diagnostics $23.9306/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252663175 CMS
Novartis Pharmaceuticals Corporation $94.0705/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200207630 CMS
Novartis Pharmaceuticals Corporation $84.5405/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200265200 CMS
Novartis Pharmaceuticals Corporation $2,450.0005/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200265202 CMS
Novartis Pharmaceuticals Corporation $18.2904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200207632 CMS
PFIZER INC. $23.6204/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229053338 CMS
Exelixis Inc. $133.6402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218802357 CMS
Novartis Pharmaceuticals Corporation $48.8902/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200207622 CMS
PFIZER INC. $149.1702/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229113718 CMS
Novartis Pharmaceuticals Corporation $22.0402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200207624 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $156.62 1
PY2023 $503.44 11
PY2024 $161.34 6
PY2025 $10,277.21 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $220,662.04 21
PY2024 Principal investigator $169,149.54 18
PY2023 Principal investigator $83,135.64 3
PY2022 Principal investigator $197,817.83 17
PY2021 Principal investigator $171,207.40 2
PY2020 Principal investigator $24,741.25 4
PY2019 Principal investigator $339.06 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,951.10 12/20/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078958517
Principal investigator 1 Janssen Research & Development, LLC $2,361.95 11/25/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078958513
Principal investigator 1 Janssen Research & Development, LLC $2,361.95 10/24/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078957019
Principal investigator 1 Janssen Research & Development, LLC $1,850.00 10/15/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078956855
Principal investigator 1 Janssen Research & Development, LLC $400.00 10/15/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078957013
Principal investigator 1 Janssen Research & Development, LLC $565.00 10/15/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078957175
Principal investigator 1 Janssen Research & Development, LLC $42,801.54 10/10/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078957443
Principal investigator 1 Exelixis Inc. $2,385.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626865
Principal investigator 1 Exelixis Inc. $1,550.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626867
Principal investigator 1 Exelixis Inc. $2,000.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626869
Principal investigator 1 Exelixis Inc. $2,036.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626871
Principal investigator 1 Exelixis Inc. $2,000.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626873
Principal investigator 1 Exelixis Inc. $1,000.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626875
Principal investigator 1 Exelixis Inc. $11,000.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626877
Principal investigator 1 Exelixis Inc. $1,000.00 09/04/2024 Non-covered Recipient Entity
Baptist Health South Florida, Inc
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1138626879
Principal investigator 1 Janssen Research & Development, LLC $7,508.00 08/16/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078957563
Principal investigator 1 Janssen Research & Development, LLC $2,109.00 08/16/2024 Non-covered Recipient Entity
Bapt Hlth Miami Cancer Inst
17000139BLC2002 No dispute reported 06/30/2026 1078958515
Principal investigator 1 Astellas US Technologies $84,270.00 01/29/2024 Non-covered Recipient Entity
Miami Cancer Institute
Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer No dispute reported 06/30/2026 1120281316